Voice your opinion on congressional bill HR6227-118 and let lawmakers know your stance with UnPac!

Main Subject: Health

Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.

S3220-118, HR6731-118, S3464-118,

House committee actions Actions

Committee
Nov. 10 2023	Referred to the Subcommittee on Health.

House floor actions Actions

IntroReferral
Nov. 03 2023	Referred to the House Committee on Energy and Commerce.

Library of Congress Actions

IntroReferral
Nov. 03 2023	Introduced in House Introduced in House

House bill HR6227-118

Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

Promote the cause!

Or use this QR code